Moderna, BioNTech Lead Covid Sell-Off After Pfizer Slashes Its Outlook By $9 BillionInvestors Business Daily • 10/16/23
Vaccine Stocks—Including Pfizer, Moderna, BioNTech And Novavax—Slide Amid Plummeting DemandForbes • 10/16/23
BioNTech's stock sinks after disclosing expected charge of up to nearly $1 billion resulting from Pfizer's write offs of COVID productsMarket Watch • 10/16/23
Pfizer shares fall on guidance cut, weighing on BioNTech and Moderna stocks, and other shares on the moveMarket Watch • 10/16/23
Everest Medicines' Licensing Partner Pfizer Announces U.S. FDA Approves Etrasimod for Adults with Moderately to Severely Active Ulcerative ColitisPRNewsWire • 10/15/23
Astellas to Share New Data Across Hard-to-Treat Cancers During ESMO Congress 2023PRNewsWire • 10/15/23
Pfizer Launches $3.5 Billion Cost-Cutting Program Amid Declining Covid Vaccine SalesForbes • 10/13/23
Pfizer slashes full-year earnings and revenue guidance as Covid treatment, vaccine sales slumpCNBC • 10/13/23
Pfizer's stock sinks after company cuts outlook on lower demand for COVID productsMarket Watch • 10/13/23
Pfizer Amends U.S. Government Paxlovid Supply Agreement and Updates Full-Year 2023 GuidanceBusiness Wire • 10/13/23